primary antibodies from a focal adhesion protein antibody sampler kit cell signaling technology Search Results


93
R&D Systems anti il 20 antibody
Anti Il 20 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti il 20 antibody/product/R&D Systems
Average 93 stars, based on 1 article reviews
anti il 20 antibody - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

96
Bioss β actin antibody
β Actin Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/β actin antibody/product/Bioss
Average 96 stars, based on 1 article reviews
β actin antibody - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

92
Cell Signaling Technology Inc primary antibodies from a focal adhesion protein antibody sampler kit cell signaling technology
Primary Antibodies From A Focal Adhesion Protein Antibody Sampler Kit Cell Signaling Technology, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary antibodies from a focal adhesion protein antibody sampler kit cell signaling technology/product/Cell Signaling Technology Inc
Average 92 stars, based on 1 article reviews
primary antibodies from a focal adhesion protein antibody sampler kit cell signaling technology - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

94
Bio-Rad proteolipid protein plp
Proteolipid Protein Plp, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proteolipid protein plp/product/Bio-Rad
Average 94 stars, based on 1 article reviews
proteolipid protein plp - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

92
R&D Systems anti il 4
Anti Il 4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti il 4/product/R&D Systems
Average 92 stars, based on 1 article reviews
anti il 4 - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

90
Novus Biologicals anti influenza a m2 antibody 14c2
Anti Influenza A M2 Antibody 14c2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti influenza a m2 antibody 14c2/product/Novus Biologicals
Average 90 stars, based on 1 article reviews
anti influenza a m2 antibody 14c2 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

enos  (Bioss)
93
Bioss enos
Enos, supplied by Bioss, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/enos/product/Bioss
Average 93 stars, based on 1 article reviews
enos - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

92
R&D Systems anti s100a8
Anti S100a8, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti s100a8/product/R&D Systems
Average 92 stars, based on 1 article reviews
anti s100a8 - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

95
Novus Biologicals glycogen synthase
Glycogen Synthase, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/glycogen synthase/product/Novus Biologicals
Average 95 stars, based on 1 article reviews
glycogen synthase - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

95
Novus Biologicals anti gfp antibody
Physiological relevance of glucose deprivation on SMAR1-p53 IRES association. (a) Western blot of A549-cell extracts after indicated duration of glucose starvation, blotted with CM1 (left panel) <t>or</t> <t>Pab240</t> antibody (right panel). (b,c) Quantitative PCR of p21, mdm2 and SFN mRNA levels normalized to GAPDH in A549 cells (b) and HCT116 cells (c) following 0, 8 and 30 h of glucose deprivation. (d) Western blot of A549- and HepG2-cell extracts showing the expression pattern of SMAR1 in a time-dependent manner post-glucose deprivation. Glucose was deprived for indicated time in hours and the cells were harvested at the given time points. (e) Western blot analysis of A549-cell extracts transfected with non-targetting (Nsp) or SMAR1 siRNA for 96 h, followed by glucose starvation for 30 h. Δ40p53 levels are indicated by an arrow. (f) Reverse transcriptase-quantitative PCR analysis of RNA extracted from ribonucleoprotein complexes immunoprecipitated from non-starved or 8-h glucose-starved A549 cells using anti-SMAR1, anti-PTB antibodies or IgG-isotype control. Primers corresponding to 1–251 region of p53 RNA were used. Results represented as fold change over and above RNA immunoprecipitated from non-starved cells with IgG control antibody. (g) Reverse transcriptase-quantitative PCR analysis of RNA extracted from ribonucleoprotein complexes immunoprecipitated from non-starved or 8-h glucose-starved H1299 cells transfected with <t>GFP-hp-5'UTR-p53-bicistronic</t> mRNA using anti-SMAR1, anti-PTB antibodies or IgG-isotype control. Primers corresponding to 1–251 region of p53 RNA were used. Results represented as fold change over and above RNA immunoprecipitated from non-starved cells with IgG control antibody. (h) FACS analysis of cell populations in G1, S or G2-M phases in H1299-NS and H1299-S3 cells. The cells were transfected with 14A (top row), 14A-M2 (middle row) or pEGFP (bottom row). Cell cycle was arrested by double-thymidine treatment, then cells were glucose starved for 0, 4, 8, 12, 24 and 30 h and harvested at these time points with corresponding unstarved control cells. (i) Glucose replenishment (rescue) for 12 and 24 h following 8 h of glucose deprivation in H1299 cells transfected with pGFP-hp-p53-5'UTR-cDNA plasmid. Western blots depict SMAR1, p53, Δ40p53 and actin levels. Graphs represent lane-wise densitometric analysis. (j) Glucose replenishment (rescue) for 12 and 24 h following 8 h of glucose deprivation in A549 cells. Western blots depict endogenous p53 and Δ40p53 (shown by an arrow) as well as SMAR1 and actin levels. Graphs represent lane-wise densitometric values. (k) Quantitative PCR for levels of p53-target mRNAs p21/Cip1 (CDK-interacting protein1), SFN (stratifin alias 14-3-3σ), Bax (Bcl-2 associated X), TIGAR (TP53-induced glycolysis and apoptosis regulator), PIDD (P53-induced DNA damage) and Mdm2 (murine double minute 2) in H1299 cells transfected with pGFP-hp-p53-5'UTR-cDNA plasmid, starved of glucose for 8 h (8 h) and then rescued by glucose replenishment for 12 h (8 h/12 h) and 24 h (8 h/24 h). Results represented as fold change in mRNA levels compared to non-starved, transfected cells, n=3
Anti Gfp Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti gfp antibody/product/Novus Biologicals
Average 95 stars, based on 1 article reviews
anti gfp antibody - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

94
R&D Systems anti epha2 n terminal mab
Physiological relevance of glucose deprivation on SMAR1-p53 IRES association. (a) Western blot of A549-cell extracts after indicated duration of glucose starvation, blotted with CM1 (left panel) <t>or</t> <t>Pab240</t> antibody (right panel). (b,c) Quantitative PCR of p21, mdm2 and SFN mRNA levels normalized to GAPDH in A549 cells (b) and HCT116 cells (c) following 0, 8 and 30 h of glucose deprivation. (d) Western blot of A549- and HepG2-cell extracts showing the expression pattern of SMAR1 in a time-dependent manner post-glucose deprivation. Glucose was deprived for indicated time in hours and the cells were harvested at the given time points. (e) Western blot analysis of A549-cell extracts transfected with non-targetting (Nsp) or SMAR1 siRNA for 96 h, followed by glucose starvation for 30 h. Δ40p53 levels are indicated by an arrow. (f) Reverse transcriptase-quantitative PCR analysis of RNA extracted from ribonucleoprotein complexes immunoprecipitated from non-starved or 8-h glucose-starved A549 cells using anti-SMAR1, anti-PTB antibodies or IgG-isotype control. Primers corresponding to 1–251 region of p53 RNA were used. Results represented as fold change over and above RNA immunoprecipitated from non-starved cells with IgG control antibody. (g) Reverse transcriptase-quantitative PCR analysis of RNA extracted from ribonucleoprotein complexes immunoprecipitated from non-starved or 8-h glucose-starved H1299 cells transfected with <t>GFP-hp-5'UTR-p53-bicistronic</t> mRNA using anti-SMAR1, anti-PTB antibodies or IgG-isotype control. Primers corresponding to 1–251 region of p53 RNA were used. Results represented as fold change over and above RNA immunoprecipitated from non-starved cells with IgG control antibody. (h) FACS analysis of cell populations in G1, S or G2-M phases in H1299-NS and H1299-S3 cells. The cells were transfected with 14A (top row), 14A-M2 (middle row) or pEGFP (bottom row). Cell cycle was arrested by double-thymidine treatment, then cells were glucose starved for 0, 4, 8, 12, 24 and 30 h and harvested at these time points with corresponding unstarved control cells. (i) Glucose replenishment (rescue) for 12 and 24 h following 8 h of glucose deprivation in H1299 cells transfected with pGFP-hp-p53-5'UTR-cDNA plasmid. Western blots depict SMAR1, p53, Δ40p53 and actin levels. Graphs represent lane-wise densitometric analysis. (j) Glucose replenishment (rescue) for 12 and 24 h following 8 h of glucose deprivation in A549 cells. Western blots depict endogenous p53 and Δ40p53 (shown by an arrow) as well as SMAR1 and actin levels. Graphs represent lane-wise densitometric values. (k) Quantitative PCR for levels of p53-target mRNAs p21/Cip1 (CDK-interacting protein1), SFN (stratifin alias 14-3-3σ), Bax (Bcl-2 associated X), TIGAR (TP53-induced glycolysis and apoptosis regulator), PIDD (P53-induced DNA damage) and Mdm2 (murine double minute 2) in H1299 cells transfected with pGFP-hp-p53-5'UTR-cDNA plasmid, starved of glucose for 8 h (8 h) and then rescued by glucose replenishment for 12 h (8 h/12 h) and 24 h (8 h/24 h). Results represented as fold change in mRNA levels compared to non-starved, transfected cells, n=3
Anti Epha2 N Terminal Mab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti epha2 n terminal mab/product/R&D Systems
Average 94 stars, based on 1 article reviews
anti epha2 n terminal mab - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

95
R&D Systems apc anti rat sca 1
Physiological relevance of glucose deprivation on SMAR1-p53 IRES association. (a) Western blot of A549-cell extracts after indicated duration of glucose starvation, blotted with CM1 (left panel) <t>or</t> <t>Pab240</t> antibody (right panel). (b,c) Quantitative PCR of p21, mdm2 and SFN mRNA levels normalized to GAPDH in A549 cells (b) and HCT116 cells (c) following 0, 8 and 30 h of glucose deprivation. (d) Western blot of A549- and HepG2-cell extracts showing the expression pattern of SMAR1 in a time-dependent manner post-glucose deprivation. Glucose was deprived for indicated time in hours and the cells were harvested at the given time points. (e) Western blot analysis of A549-cell extracts transfected with non-targetting (Nsp) or SMAR1 siRNA for 96 h, followed by glucose starvation for 30 h. Δ40p53 levels are indicated by an arrow. (f) Reverse transcriptase-quantitative PCR analysis of RNA extracted from ribonucleoprotein complexes immunoprecipitated from non-starved or 8-h glucose-starved A549 cells using anti-SMAR1, anti-PTB antibodies or IgG-isotype control. Primers corresponding to 1–251 region of p53 RNA were used. Results represented as fold change over and above RNA immunoprecipitated from non-starved cells with IgG control antibody. (g) Reverse transcriptase-quantitative PCR analysis of RNA extracted from ribonucleoprotein complexes immunoprecipitated from non-starved or 8-h glucose-starved H1299 cells transfected with <t>GFP-hp-5'UTR-p53-bicistronic</t> mRNA using anti-SMAR1, anti-PTB antibodies or IgG-isotype control. Primers corresponding to 1–251 region of p53 RNA were used. Results represented as fold change over and above RNA immunoprecipitated from non-starved cells with IgG control antibody. (h) FACS analysis of cell populations in G1, S or G2-M phases in H1299-NS and H1299-S3 cells. The cells were transfected with 14A (top row), 14A-M2 (middle row) or pEGFP (bottom row). Cell cycle was arrested by double-thymidine treatment, then cells were glucose starved for 0, 4, 8, 12, 24 and 30 h and harvested at these time points with corresponding unstarved control cells. (i) Glucose replenishment (rescue) for 12 and 24 h following 8 h of glucose deprivation in H1299 cells transfected with pGFP-hp-p53-5'UTR-cDNA plasmid. Western blots depict SMAR1, p53, Δ40p53 and actin levels. Graphs represent lane-wise densitometric analysis. (j) Glucose replenishment (rescue) for 12 and 24 h following 8 h of glucose deprivation in A549 cells. Western blots depict endogenous p53 and Δ40p53 (shown by an arrow) as well as SMAR1 and actin levels. Graphs represent lane-wise densitometric values. (k) Quantitative PCR for levels of p53-target mRNAs p21/Cip1 (CDK-interacting protein1), SFN (stratifin alias 14-3-3σ), Bax (Bcl-2 associated X), TIGAR (TP53-induced glycolysis and apoptosis regulator), PIDD (P53-induced DNA damage) and Mdm2 (murine double minute 2) in H1299 cells transfected with pGFP-hp-p53-5'UTR-cDNA plasmid, starved of glucose for 8 h (8 h) and then rescued by glucose replenishment for 12 h (8 h/12 h) and 24 h (8 h/24 h). Results represented as fold change in mRNA levels compared to non-starved, transfected cells, n=3
Apc Anti Rat Sca 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apc anti rat sca 1/product/R&D Systems
Average 95 stars, based on 1 article reviews
apc anti rat sca 1 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

Image Search Results


Physiological relevance of glucose deprivation on SMAR1-p53 IRES association. (a) Western blot of A549-cell extracts after indicated duration of glucose starvation, blotted with CM1 (left panel) or Pab240 antibody (right panel). (b,c) Quantitative PCR of p21, mdm2 and SFN mRNA levels normalized to GAPDH in A549 cells (b) and HCT116 cells (c) following 0, 8 and 30 h of glucose deprivation. (d) Western blot of A549- and HepG2-cell extracts showing the expression pattern of SMAR1 in a time-dependent manner post-glucose deprivation. Glucose was deprived for indicated time in hours and the cells were harvested at the given time points. (e) Western blot analysis of A549-cell extracts transfected with non-targetting (Nsp) or SMAR1 siRNA for 96 h, followed by glucose starvation for 30 h. Δ40p53 levels are indicated by an arrow. (f) Reverse transcriptase-quantitative PCR analysis of RNA extracted from ribonucleoprotein complexes immunoprecipitated from non-starved or 8-h glucose-starved A549 cells using anti-SMAR1, anti-PTB antibodies or IgG-isotype control. Primers corresponding to 1–251 region of p53 RNA were used. Results represented as fold change over and above RNA immunoprecipitated from non-starved cells with IgG control antibody. (g) Reverse transcriptase-quantitative PCR analysis of RNA extracted from ribonucleoprotein complexes immunoprecipitated from non-starved or 8-h glucose-starved H1299 cells transfected with GFP-hp-5'UTR-p53-bicistronic mRNA using anti-SMAR1, anti-PTB antibodies or IgG-isotype control. Primers corresponding to 1–251 region of p53 RNA were used. Results represented as fold change over and above RNA immunoprecipitated from non-starved cells with IgG control antibody. (h) FACS analysis of cell populations in G1, S or G2-M phases in H1299-NS and H1299-S3 cells. The cells were transfected with 14A (top row), 14A-M2 (middle row) or pEGFP (bottom row). Cell cycle was arrested by double-thymidine treatment, then cells were glucose starved for 0, 4, 8, 12, 24 and 30 h and harvested at these time points with corresponding unstarved control cells. (i) Glucose replenishment (rescue) for 12 and 24 h following 8 h of glucose deprivation in H1299 cells transfected with pGFP-hp-p53-5'UTR-cDNA plasmid. Western blots depict SMAR1, p53, Δ40p53 and actin levels. Graphs represent lane-wise densitometric analysis. (j) Glucose replenishment (rescue) for 12 and 24 h following 8 h of glucose deprivation in A549 cells. Western blots depict endogenous p53 and Δ40p53 (shown by an arrow) as well as SMAR1 and actin levels. Graphs represent lane-wise densitometric values. (k) Quantitative PCR for levels of p53-target mRNAs p21/Cip1 (CDK-interacting protein1), SFN (stratifin alias 14-3-3σ), Bax (Bcl-2 associated X), TIGAR (TP53-induced glycolysis and apoptosis regulator), PIDD (P53-induced DNA damage) and Mdm2 (murine double minute 2) in H1299 cells transfected with pGFP-hp-p53-5'UTR-cDNA plasmid, starved of glucose for 8 h (8 h) and then rescued by glucose replenishment for 12 h (8 h/12 h) and 24 h (8 h/24 h). Results represented as fold change in mRNA levels compared to non-starved, transfected cells, n=3

Journal: Cell Death and Differentiation

Article Title: Reversible induction of translational isoforms of p53 in glucose deprivation

doi: 10.1038/cdd.2014.220

Figure Lengend Snippet: Physiological relevance of glucose deprivation on SMAR1-p53 IRES association. (a) Western blot of A549-cell extracts after indicated duration of glucose starvation, blotted with CM1 (left panel) or Pab240 antibody (right panel). (b,c) Quantitative PCR of p21, mdm2 and SFN mRNA levels normalized to GAPDH in A549 cells (b) and HCT116 cells (c) following 0, 8 and 30 h of glucose deprivation. (d) Western blot of A549- and HepG2-cell extracts showing the expression pattern of SMAR1 in a time-dependent manner post-glucose deprivation. Glucose was deprived for indicated time in hours and the cells were harvested at the given time points. (e) Western blot analysis of A549-cell extracts transfected with non-targetting (Nsp) or SMAR1 siRNA for 96 h, followed by glucose starvation for 30 h. Δ40p53 levels are indicated by an arrow. (f) Reverse transcriptase-quantitative PCR analysis of RNA extracted from ribonucleoprotein complexes immunoprecipitated from non-starved or 8-h glucose-starved A549 cells using anti-SMAR1, anti-PTB antibodies or IgG-isotype control. Primers corresponding to 1–251 region of p53 RNA were used. Results represented as fold change over and above RNA immunoprecipitated from non-starved cells with IgG control antibody. (g) Reverse transcriptase-quantitative PCR analysis of RNA extracted from ribonucleoprotein complexes immunoprecipitated from non-starved or 8-h glucose-starved H1299 cells transfected with GFP-hp-5'UTR-p53-bicistronic mRNA using anti-SMAR1, anti-PTB antibodies or IgG-isotype control. Primers corresponding to 1–251 region of p53 RNA were used. Results represented as fold change over and above RNA immunoprecipitated from non-starved cells with IgG control antibody. (h) FACS analysis of cell populations in G1, S or G2-M phases in H1299-NS and H1299-S3 cells. The cells were transfected with 14A (top row), 14A-M2 (middle row) or pEGFP (bottom row). Cell cycle was arrested by double-thymidine treatment, then cells were glucose starved for 0, 4, 8, 12, 24 and 30 h and harvested at these time points with corresponding unstarved control cells. (i) Glucose replenishment (rescue) for 12 and 24 h following 8 h of glucose deprivation in H1299 cells transfected with pGFP-hp-p53-5'UTR-cDNA plasmid. Western blots depict SMAR1, p53, Δ40p53 and actin levels. Graphs represent lane-wise densitometric analysis. (j) Glucose replenishment (rescue) for 12 and 24 h following 8 h of glucose deprivation in A549 cells. Western blots depict endogenous p53 and Δ40p53 (shown by an arrow) as well as SMAR1 and actin levels. Graphs represent lane-wise densitometric values. (k) Quantitative PCR for levels of p53-target mRNAs p21/Cip1 (CDK-interacting protein1), SFN (stratifin alias 14-3-3σ), Bax (Bcl-2 associated X), TIGAR (TP53-induced glycolysis and apoptosis regulator), PIDD (P53-induced DNA damage) and Mdm2 (murine double minute 2) in H1299 cells transfected with pGFP-hp-p53-5'UTR-cDNA plasmid, starved of glucose for 8 h (8 h) and then rescued by glucose replenishment for 12 h (8 h/12 h) and 24 h (8 h/24 h). Results represented as fold change in mRNA levels compared to non-starved, transfected cells, n=3

Article Snippet: Samples were then analyzed by western blotting using rabbit-raised CM-1 antibody (kind gift from Professor Robin Fahraeus, INSERM), anti-SMAR1 antibody (Abcam, Cambridge, UK), mouse-raised DO1 and Pab240 antibodies (Santa Cruz Biotechnology, Dallas, TX, USA) or rabbit-raised anti-GFP antibody (IMG5127, Imgenex, Bhubaneswar, Odisha, India) followed by secondary antibody (horseradish peroxidase-conjugated anti-rabbit IgG; Sigma-Aldrich).

Techniques: Western Blot, Real-time Polymerase Chain Reaction, Expressing, Transfection, Reverse Transcription, Immunoprecipitation, Plasmid Preparation